Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fentanyl buccal - BioDelivery Sciences/TTY Biopharm

Drug Profile

Fentanyl buccal - BioDelivery Sciences/TTY Biopharm

Alternative Names: BEMA-Fentanyl; Breakyl; Fentanyl buccal soluble film; Fentanyl transmucosal - BioDelivery Sciences; Onsolis; Painkyl

Latest Information Update: 04 Aug 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator QLT USA
  • Developer BioDelivery Sciences International; Meda; TTY Biopharm
  • Class Amides; Benzene derivatives; General anaesthetics; Opioid analgesics; Piperidines; Small molecules
  • Mechanism of Action Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Cancer pain

Most Recent Events

  • 02 Aug 2022 Adalvo acquired fentanyl buccal soluble film (Onsolis®), taking over all existing business and all market authorizations, globally, including the US
  • 22 Mar 2022 BioDelivery Sciences International has been acquired by Collegium Pharmaceutical
  • 08 Jul 2019 Launched for Cancer pain in USA, prior July 2019 (Buccal)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top